Vaccine makers urge speedy accord on pandemic plan

By Laura MacInnis

GENEVA (Reuters) - Governments need to overcome their “pandemic fatigue” and act quickly to finalize a response plan to potential flu threats, leading drugmakers said on Thursday.

The pharmaceutical industry is “very close to ready” to respond to a potential outbreak by shifting seasonal flu vaccine production to more targeted pandemic ones, said Stephen Gardner of GSK Biologics.

But Gardner told a news briefing that countries needed to stop stalling and craft an accord on sharing samples of virus strains with pandemic potential for tests that accelerate efforts to formulate effective vaccines.

“We don’t have time to negotiate a new agreement when a pandemic arises. We need to get on with manufacturing quickly,” he said. “Time is of the essence to ensure good vaccine supply.”

The World Health Organization (WHO) will host an inter-governmental meeting next week where the United Nations agency’s member states will discuss sensitive questions about virus sample sharing and access to vaccines in case of a flu pandemic.

Indonesia, the country most affected by H5N1 bird flu, has resisted providing viral samples to the international community because it argues that material is then used by big drugmakers to create vaccines that poorer countries cannot afford or use.

TRANSFER AGREEMENT

The International Federation of Pharmaceutical Manufacturers and Associations (IFPMA) wants to be included in WHO-hosted negotiations about a “material transfer agreement” covering the strains of viruses companies need to develop pandemic vaccines.

“We would like to be involved in the detail of the discussion,” Gardner told the briefing in Geneva, where the talks will occur December 8-13.

According to the IFPMA, the pharmaceutical industry has invested more than $4 billion in tools to prevent and stop pandemic flu, which generally strikes every 20 to 30 years. The last known outbreak was in 1968.

Tony Colegate of Novartis Vaccines said that unless manufacturers have advance notice of dangerous strains, it would take 4 to 6 months to make an effective vaccine from the moment a pandemic is announced.

“If the WHO don’t get the samples from the national centers, they don’t know what is going on and they can’t tell us which strains to use,” he told the briefing.

While H5N1 bird flu is now grabbing fewer headlines than a few years ago, when fears were high that it would morph into an easily-spreadable strain, Gardner said it continued to present a risk given its very high fatality rate of 40 to 60 percent.

“There is definitely a decrease in the interest in pandemics … (but) the threat is still there,” he said. “If the virus does adapt and start spreading like a normal flu, we are in trouble.”

(Editing by Keith Weir)

Source

--------------------------------------------------------------------------------------------
Related Posts:


WASHINGTON (Reuters) - Smokers should be vaccinated against a pneumonia-causing germ, along with children and the elderly, U.S. federal advisers recommended on Wednesday. If accepted by the Centers for Disease Control and Prevention, it would be the first vaccine recommendation aimed specifically at smokers. The vaccines, called pneumococcal vaccines, prevent infection with several strains of Streptococcus pneumonia,

Full Post: Smokers should get pneumonia vaccine: U.S. advisers
--------------------------------------------------------------------------------------------

By Gene Emery BOSTON (Reuters) - A newer vaccine that targets the most common form of the polio virus works up to four times better than the conventional vaccine that tries to protect against all three types of the crippling disease, researchers said on Wednesday. The monovalent vaccine may help speed the fight to eradicate polio, U.S.

Full Post: Newer vaccine seen as better for polio hot spots
--------------------------------------------------------------------------------------------

By Megan Rauscher NEW YORK (Reuters Health) - Even in an influenza season where there is not an optimal match between circulating strains of influenza and the strains contained in the influenza vaccine, the vaccine is likely to significantly protect young children, ages 6 to 59 months, against influenza, new research indicates. Influenza vaccine effectiveness has not

Full Post: Influenza vaccine effective in young children
--------------------------------------------------------------------------------------------

NEW YORK (Reuters Health) - A combination vaccine against diphtheria, tetanus, pertussis, polio and flu, which is routinely used in Canadian children, has been shown to be effective and well tolerated in a U.S. study. The randomized trial was conducted to support U.S. licensure of the vaccine known as DTaP5-IPV-Hib, which incorporates diphtheria-tetanus-5-component acellular pertussis (DTaP5),

Full Post: Combination vaccine safe and effective for infants
--------------------------------------------------------------------------------------------

NEW YORK (Reuters Health) - A vaccine to protect against infection with the bird flu virus, the pathogen experts fear is capable of causing pandemic disease in humans, proved safe and effective in a preliminary clinical trial with children, mirroring the results of a recent trial conducted in adults, Hungarian researchers report in the Pediatric

Full Post: Bird flu vaccine protects children

Site Navigation

Most Read

Search